Korro Bio, Inc. (KRRO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 37 | 0 | 0 | 0 | 2 | 6 | 2 | - |
| Operating profit | $m | -87 | -76 | ||||||
| Net profit | $m | -27 | -22 | -58 | -81 | -84 | -117 | -107 | -54 |
| EPS reported | $ | -12.48 | -10.01 | ||||||
| Operating cashflow per share | $ | -8.36 | -3.86 | ||||||
| Capex per share | $ | 0.06 | 0.02 | ||||||
| FCF per share | $ | -8.42 | -3.87 | ||||||
| Free cash flow | $m | -79 | -68 | ||||||
| Net debt | $m | -75 | -115 | ||||||
| Book value equity | $m | 51 | 103 | ||||||
| Book value per share | $ | 5.47 | 5.86 | ||||||
| Number of shares | m | 9.4 | 17.62 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.46 | 0.73 | ||||||
| P/S LTM | x | 11.77 | 31.59 | ||||||
| P/FCF LTM | x | -0.95 | -1.10 | ||||||
| EV/EBITDA LTM | x | -1.17 | -1.35 | ||||||
| EV/Sales LTM | x | 15.16 | 62.76 | ||||||
| Earnings Yield LTM | % | -1.56% | -45.58% | ||||||
| FCF Yield | % | -105.08% | -90.71% | ||||||
| Quality | |||||||||
| ROE | % | -227.96% | -114.26% | ||||||
| ROIC | % | -83.79% | -49.21% | ||||||
| Operating margin | % | -13.66% | -31.77% | ||||||
| Gross margin | % | +33.04% | +72.75% | ||||||
| FCF/Sales | % | -1237.2% | -2865.9% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +181.46% | +4.89% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.82 | -1.62 | ||||||
| Net Debt/EBITDA | x | -0.26 | -0.24 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -1.46 | -1.11 | ||||||
| Gross debt/equity | x | 0.85 | 0.41 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free